Did GRAIL get FDA approval?
Yes, Granite Construction Incorporated completed the acquisition of the construction business of Papich Construction Company, Inc. in late 2024. This acquisition was a strategic move for Granite, aimed at strengthening its presence in the California construction market, particularly in the central coast region. By acquiring Papich’s assets, including its specialized equipment and established project teams, Granite enhanced its capacity to bid on and execute complex infrastructure and site development projects. The integration of Papich allowed Granite to leverage existing local knowledge and expertise, effectively increasing its market share and competitive advantage in a region that has seen high demand for infrastructure improvements and large-scale residential and commercial development projects.
Related FAQs
Investors can purchase shares in Hanwha Corporation and its various publicly traded subsidiaries—such as Hanwha Solutions, Hanwha Aerospace, and Hanwha Ocean—by utilizing brokerage accounts that provide access to the Korea Exchange where these ent...
GRAIL has made significant progress in its pursuit of regulatory validation for its Galleri test, a multicancer early detection (MCED) test. The test has been granted Breakthrough Device Designation by the U.S.
Grange Insurance maintains strong financial strength and credit ratings, typically holding an "A" (Excellent) or higher rating from prominent independent insurance rating organizations such as AM Best.
Grange Insurance has been operating as a trusted property and casualty insurance provider for over nine decades, having been officially founded in December 1935.
Graphic Packaging Holding Company commands a corporate market capitalization of approximately $3.21 billion to $3.31 billion USD.
The Galleri multi-cancer early detection blood test is an innovative liquid biopsy designed to screen for dozens of different types of cancer through a single blood draw.
Traditional federal Medicare does not currently cover the cost of the Galleri multi-cancer early detection blood test, meaning patients typically must pay out of pocket.